Nuveen
PHAT icon

Nuveen’s Phathom Pharmaceuticals PHAT Stock Holding History

Nuveen’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
127,127
+9,826
+8% +$112K ﹤0.01% 2773
2026
Q1 		$1.3M Buy
117,301
+8,455
+8% +$107K ﹤0.01% 2465
2025
Q4 		$1.81M Sell
108,846
-1,264
-1% -$18.1K ﹤0.01% 2331
2025
Q3 		$1.3M Hold
110,110
– – ﹤0.01% 2496
2025
Q2 		$1.06M Buy
110,110
+8,590
+8% +$47.5K ﹤0.01% 2576
2025
Q1 		$637K Sell
101,520
-46,003
-31% -$279K ﹤0.01% 2822
2024
Q4 		$1.2M Sell
147,523
-6,851
-4% -$84.8K ﹤0.01% 2633
2024
Q3 		$2.79M Buy
154,374
+13,352
+9% +$187K ﹤0.01% 2261
2024
Q2 		$1.45M Sell
141,022
-121,026
-46% -$1.25M ﹤0.01% 2541
2024
Q1 		$2.78M Sell
262,048
-42,561
-14% -$361K ﹤0.01% 2249
2023
Q4 		$2.78M Buy
304,609
+16,775
+6% +$145K ﹤0.01% 2258
2023
Q3 		$2.98M Buy
287,834
+106,225
+58% +$1.46M ﹤0.01% 2125
2023
Q2 		$2.6M Buy
181,609
+73,325
+68% +$845K ﹤0.01% 2232
2023
Q1 		$773K Buy
108,284
+357
+0.3% +$3.14K ﹤0.01% 2696
2022
Q4 		$1.21M Sell
107,927
-9,652
-8% -$99.5K ﹤0.01% 2612
2022
Q3 		$1.3M Buy
117,579
+2,036
+2% +$19.4K ﹤0.01% 2616
2022
Q2 		$976K Buy
115,543
+53,962
+88% +$555K ﹤0.01% 2789
2022
Q1 		$823K Buy
61,581
+1,363
+2% +$22K ﹤0.01% 2876
2021
Q4 		$1.18M Sell
60,218
-9,377
-13% -$221K ﹤0.01% 2798
2021
Q3 		$2.23M Sell
69,595
-24,490
-26% -$814K ﹤0.01% 2618
2021
Q2 		$3.19M Buy
94,085
+28,129
+43% +$1.01M ﹤0.01% 2485
2021
Q1 		$2.48M Buy
65,956
+2,950
+5% +$123K ﹤0.01% 2518
2020
Q4 		$2.09M Buy
63,006
+1,335
+2% +$54.1K ﹤0.01% 2487
2020
Q3 		$2.26M Buy
61,671
+11,633
+23% +$403K ﹤0.01% 2319
2020
Q2 		$1.65M Buy
50,038
+14,546
+41% +$559K ﹤0.01% 2418
2020
Q1 		$917K Buy
35,492
+147
+0.4% +$4.91K ﹤0.01% 2551
2019
Q4 		$1.1M Buy
+35,345
New +$888K ﹤0.01% 2654

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Nuveen's PHAT Position: Q2 2026 in Review

Nuveen increased its Phathom Pharmaceuticals (PHAT) stake by 8.4% in Q2 2026, buying an estimated $112K and bringing the position to 127,127 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

Nuveen first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.19M in Q2 2021. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Nuveen held 127,127 shares of Phathom Pharmaceuticals worth $1.38M as of Q2 2026.
  • Nuveen bought 9,826 Phathom Pharmaceuticals shares in Q2 2026, an estimated $112K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2773 holding.
  • Nuveen first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Nuveen's Phathom Pharmaceuticals position peaked at $3.19M in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.